Colinz Laboratories

Colinz Laboratories FCF/Debt

The Free Cash Flow to Debt Ratio of Colinz Laboratories (531210.BO) as of Oct 15, 2026 is -267.69 %. In the previous year, Free Cash Flow to Debt Ratio was 181.59 % — a change of -247.41% (lower).

FCF/Debt

-267.69 %

YoY

-247.41%

Last updated:

Free Cash Flow to Debt Ratio of Colinz Laboratories is 2025 -267.69 % . Free Cash Flow to Debt Ratio of Colinz Laboratories was 2024 181.59 % . It decreases by -247.41% lower compared to the previous year.

The Colinz Laboratories FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
80.03 INR
Jan 1, 2019
17.18 INR
Jan 1, 2020
141.04 INR
Jan 1, 2021
201.52 INR
Jan 1, 2022
88.67 INR
Jan 1, 2023
147.37 INR
Jan 1, 2024
181.59 INR
Jan 1, 2025
-267.69 INR
The Colinz Laboratories FCF/Debt history
YEARFCF/DebtYoY
-267.69 %-247.41%
181.59 %+23.22%
147.37 %+66.20%
88.67 %-56.00%
201.52 %+42.88%
141.04 %+721.14%
17.18 %-78.54%
80.03 %+1,422.77%
5.26 %-78.08%
23.97 %+1,113.45%
1.98 %-88.34%
16.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 531210.BO and ISIN INE923C01011, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It went public through an IPO on January 13, 2004. Colinz Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations across various dosage forms, including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company's product portfolio targets several medical conditions, such as hypertension, cholesterol, diabetes, piles, pyrexia, and malaria, with specific offerings for gynecological treatments like morning sickness, infertility, intrauterine growth restriction (IUGR), and pregnancy maintenance. Additionally, it provides hematinic, antispasmodic, anti-inflammatory, anti-allergic, and medicated shampoo products. Colinz Laboratories markets its products directly within several Indian states, including Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal, utilizing its own marketing team. The company's website is www.colinz.com. It is important to note that the company's operations and product details are based on the provided information without additional verification. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

Free Cash Flow to Debt Ratio of Colinz Laboratories is -267.69 % in 2025.

Free Cash Flow to Debt Ratio of Colinz Laboratories changed from 181.59 % to -267.69 %, representing a -247.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Colinz Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Colinz Laboratories

All Key Metrics — Colinz Laboratories